Oncology
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Early ESMO GI data suggest that a CEACAM5-targeted antibody–drug conjugate may have activity in selected patients with refractory pancreatic cancer. The opportunity is real. So is the danger of treating biomarker selection as a box-ticking exercise.
AML’s Frontline Future Starts With Finding the Mutation Fast
GIST Care Looks Beyond First-Generation KIT Control
Pancreatic Cancer Finally Gets a RAS Moment
GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race
J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Cancer Sequencing Becomes the Operating System of Precision Oncology
Personalised Cancer Vaccines Show Longer-Term Staying Power
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
Prostate Cancer Value Starts Counting Cognition
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.